The most common symptoms are pain, lack of balance, spasticity, paralysis and chronic fatigue.

The Multiple sclerosis is a disease of the immune system. whose origin is unknown.

The immune system of MS sufferers is altered from defending the body to attacking it, destroying the myelin that coats the nerve fibres, and thus hindering or even interrupting the nervous system's information processing.

The most common symptoms are pain, lack of balance, spasticity, paralysis and chronic fatigue. In most cases the way in which the that appear these symptoms make diagnosis difficult.

Although the causes of Multiple Sclerosis are not known for certain, it is known from several studies that there is a genetic factor and various environmental factors, such as lack of sun exposure, which are determining factors.

In order to diagnose MS, the patient must undergo an MRI scan, which will reveal the areas of damage, as demyelination most often occurs in the brain mass, brainstem or spinal cord.

The most common treatment is injectable interferons whose function is to control the crises suffered by patients and to delay the development of the disease.

Fortunately, medicine is advancing, and one of the latest developments in MS drug treatments is the discovery of a substance called fingolimod, marketed by the pharmaceutical company Novartis under the name Gilenya, which works by reducing disease flares and their unfavourable evolution.

The main advantage of fingolimod is that it is administered orally in capsules, thus improving the quality of life of the patient, who until now only had regular injections for the treatment of his disease.

At Biosalud we believe that with Immunogenetic Biomedicine it is possible to deactivate the genes that have activated the disease and control it in a 100%, which is why we have treatments aimed at preventing and treating this and many other diseases that affect the immune system.